{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:22:18Z","timestamp":1783606938299,"version":"3.55.0"},"reference-count":16,"publisher":"Bioscientifica","issue":"2","funder":[{"name":"Y.M.M. and T.B. are members of the University Medicine Essen Clinician Scientist Academy (UMEA), which is funded by the German Research Foundation (DFG)."}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:p>Cabozantinib has significantly improved progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) after lenvatinib and\/or sorafenib pretreatment in the phase 3 COSMIC-311 trial, leading to its approval for sequential treatment. Real-world evidence of cabozantinib remains limited, particularly in poorly differentiated thyroid cancer (PDTC). In this retrospective analysis, we included adult patients with RAIR-DTC or PDTC treated with cabozantinib as further-line treatment at the Essen Endocrine Tumor Center (June 2022\u2013July 2025). All patients had received prior targeted therapy and had documented progressive disease at cabozantinib initiation. Best overall response, PFS, overall survival (OS) and adverse events were assessed. Nineteen patients (7 DTC and 12 PDTC) were included in the safety analysis, and 17 patients were included in the efficacy assessment. Under sequential cabozantinib treatment, partial response (PR) was observed in 4\/17 (24%): 3\/4 in patients switched due to lenvatinib toxicity and 1\/13 in those switched due to progression. Median PFS was 5.4 months in DTC and 3.6 months in PDTC. Median OS from cabozantinib initiation was 13.5 months in DTC and 15.8 months in PDTC. Dose reductions or interruptions were required in 6\/19 (31.6%), and 3\/19 (15.8%) permanently discontinued cabozantinib due to toxicity. In this real-world cohort, further-line cabozantinib showed limited efficacy in RAIR-(P)DTC, especially in PDTC. Responses were more favorable when cabozantinib was initiated due to prior treatment toxicity rather than progression. The substantial toxicity highlights the need for careful management and improved therapeutic strategies in this population.<\/jats:p>","DOI":"10.1530\/erc-25-0461","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:26:42Z","timestamp":1768566402000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9441-3046","authenticated-orcid":true,"given":"Yara Maria","family":"Machlah","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn Marlene","family":"Srasra","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-667X","authenticated-orcid":true,"given":"Frank","family":"Weber","sequence":"additional","affiliation":[{"name":"2"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[{"name":"2"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-4192","authenticated-orcid":true,"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-4341","authenticated-orcid":true,"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026070909443787900_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hed.21504","article-title":"Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer","volume":"33","author":"Barney","year":"2011","journal-title":"Head Neck"},{"key":"2026070909443787900_bib2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-017-0733-1","article-title":"The treatment of advanced thyroid cancer in the age of novel targeted therapies","volume":"77","author":"Lirov","year":"2017","journal-title":"Drugs"},{"key":"2026070909443787900_bib3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443787900_bib4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/modpathol.2010.117","article-title":"Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression","volume":"23","author":"Asioli","year":"2010","journal-title":"Mod Pathol"},{"key":"2026070909443787900_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070909443787900_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070909443787900_bib7","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070909443787900_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070909443787900_bib9","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"2026070909443787900_bib10","volume-title":"Cabometyx; cabozantinib","author":"European Medicines Agency","year":"2025"},{"key":"2026070909443787900_bib11","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0225","article-title":"Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma","volume":"13","author":"Elghawy","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070909443787900_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2026070909443787900_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070909443787900_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2023.0463","article-title":"Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior vascular endothelial growth factor receptor-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study","volume":"34","author":"Capdevila","year":"2024","journal-title":"Thyroid"},{"key":"2026070909443787900_bib15","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1089\/thy.2014.0125","article-title":"A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer","volume":"24","author":"Cabanillas","year":"2014","journal-title":"Thyroid"},{"key":"2026070909443787900_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/CAD.0000000000000366","article-title":"Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults","volume":"27","author":"Nguyen","year":"2016","journal-title":"Anti Cancer Drugs"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/2\/ERC-25-0461.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/2\/ERC-25-0461.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0461\/505851\/erc-25-0461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0461\/505851\/erc-25-0461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:44:47Z","timestamp":1783604687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/2\/e250461\/75530\/Real-world-data-show-limited-efficacy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0461","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"e250461"}}